What is the best treatment for a wound infection with Enterococcus faecalis in a patient with a Penicillin (PCN) allergy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Wound Infection with Enterococcus faecalis in Penicillin-Allergic Patients

For a wound infection with Enterococcus faecalis in a patient with penicillin allergy, vancomycin 15 mg/kg IV every 12 hours is the recommended first-line treatment for 4-6 weeks, with alternatives including daptomycin 6 mg/kg IV daily or linezolid 600 mg PO/IV every 12 hours. 1

Primary Treatment Algorithm

First-Line: Vancomycin

  • Vancomycin 15 mg/kg IV every 12 hours is specifically recommended for penicillin-susceptible Enterococcus when penicillin allergy exists 1
  • The IDSA guidelines explicitly state "Vancomycin should be used only in case of penicillin allergy" for enterococcal infections 1
  • Treatment duration is typically 4-6 weeks for wound infections 1
  • Monitor serum vancomycin levels to maintain therapeutic concentrations and avoid nephrotoxicity 1

Alternative Options for Penicillin Allergy

Daptomycin:

  • Daptomycin 6 mg/kg IV every 24 hours is an effective alternative 1
  • For more severe infections or bacteremia, consider higher doses of 8-12 mg/kg/day 1, 2
  • Daptomycin demonstrates bactericidal activity against E. faecalis, including vancomycin-resistant strains 3
  • Monitor CPK levels weekly due to risk of myopathy 3

Linezolid:

  • Linezolid 600 mg PO or IV every 12 hours provides excellent oral bioavailability 1, 4
  • Particularly useful for outpatient transition therapy given oral formulation 4
  • E. faecalis maintains high susceptibility rates (>99%) to linezolid 5
  • Critical caveat: Monitor for bone marrow suppression and peripheral neuropathy with prolonged use (>2 weeks) 1, 4

Important Clinical Considerations

Species Differentiation Matters

  • E. faecalis is generally more susceptible to antibiotics than E. faecium 2
  • Approximately 97% of enterococcal infections are caused by E. faecalis 1
  • E. faecalis typically remains susceptible to penicillin, ampicillin, and vancomycin 1, 2

Resistance Patterns to Monitor

  • Vancomycin resistance in E. faecalis is less common than in E. faecium 6
  • If vancomycin resistance is detected, linezolid becomes the preferred agent 1, 2
  • Linezolid resistance in E. faecalis remains rare but can develop with prolonged exposure (mean 29.8 days) 5

Combination Therapy Considerations

  • Aminoglycosides are NOT routinely recommended for wound infections (reserved for endocarditis or bacteremia) 1
  • For severe or complicated wound infections, consider adding gentamicin only if high-level aminoglycoside resistance is absent 1
  • Synergistic combinations with daptomycin plus ampicillin or beta-lactams may be considered for severe infections, but penicillin allergy limits this approach 2

Common Pitfalls to Avoid

Do not use cephalosporins as monotherapy - Enterococci are intrinsically resistant to cephalosporins when used alone 2

Avoid fluoroquinolones - These are not recommended for enterococcal wound infections due to poor activity 1

Do not use quinupristin-dalfopristin - This agent is inactive against E. faecalis (only active against E. faecium) 2, 7

Monitor renal function closely with vancomycin - Adjust dosing based on creatinine clearance, particularly in elderly or debilitated patients 1

Reassess if clinical response is suboptimal - Consider susceptibility testing for daptomycin and linezolid if vancomycin fails 1, 6

Duration and Monitoring

  • Standard treatment duration: 4-6 weeks for wound infections 1
  • Shorter courses (7-14 days) may be appropriate for uncomplicated superficial wound infections 2
  • Clinical and laboratory monitoring for efficacy and toxicity should follow IDSA antimicrobial monitoring guidelines 1
  • If residual infected tissue remains after debridement, continue pathogen-specific therapy until adequate source control is achieved 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Antibiotic Treatment for Enterococcus faecium Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The emerging problem of linezolid-resistant enterococci.

Journal of global antimicrobial resistance, 2018

Guideline

Teicoplanin Resistance in Enterococcus faecalis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Quinupristin-dalfopristin and linezolid: evidence and opinion.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2003

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.